SVT 15435
Alternative Names: SVT15435Latest Information Update: 25 Mar 2021
Price :
$50 *
At a glance
- Originator SALVAT
- Class Antiglaucomas
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III Ocular inflammation; Ocular pain
Most Recent Events
- 25 Mar 2021 Phase III development is still ongoing for treatment of Ocular inflammation and Ocular pain that occurs after cataract surgery in Spain (SALVAT pipeline, March 2021)
- 25 Mar 2021 SVT 15435 is available for licensing as of 25 Mar 2021. https://svt.com/en/activities/#productpipe
- 25 Mar 2021 Salvat plans to launch SVT 15435 for Ocular inflammation and Pain in 2022 (Salvat pipeline, March 2021)